Drug Profile
GMI 1359
Alternative Names: GMI-1359Latest Information Update: 26 Apr 2023
Price :
$50
*
At a glance
- Originator GlycoMimetics
- Class Antineoplastics; Small molecules
- Mechanism of Action CXCR4 receptor antagonists; E-selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Osteosarcoma
- No development reported Breast cancer; Cancer
Most Recent Events
- 26 Apr 2023 GMI 1359 is available for licensing as of 26 Apr 2023. https://www.sec.gov/ix?doc=/Archives/edgar/data/1253689/000155837023004864/glyc-20221231x10k.htm
- 28 Dec 2022 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Metastatic disease) in USA (IV, Injection)
- 31 Aug 2022 GlycoMimetics terminates IND applications of GMI 1359 as of August 2022